Lovell and DefEYE Partner to Expand Access to Biovance Ocular Biologics Across Federal Healthcare Systems
Lovell Government Services and DefEYE, the provider of Biovance decellularized basement membranes for ocular use, announced a partnership to serve federal healthcare systems, including the Veterans Health Administration, the Department of Defense Military Health System, and the Indian Health Service. Under the agreement, Lovell will act as DefEYE’s Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, streamlining access to DefEYE’s ophthalmic biologic products through established federal contracting systems.
“Lovell Government Services is proud to partner with DefEYE to bring its ophthalmic-biologic products to federal healthcare providers,” said Chris Lovell, Major, USMC (Ret.), and CEO of Lovell Government Services. “By making DefEYE’s Biovance ocular portfolio available through our contract vehicles, we streamline practitioner and hospital acquisition, help agencies meet SDVOSB goals, and most importantly expand access to eye care innovations that help preserve and restore vision for the veterans we serve.”
This partnership ensures that clinicians and facilities within federal systems can efficiently obtain DefEYE’s Biovance and Biovance 3L Ocular products—innovative biologic membranes that support ocular surface healing and surgical outcomes.
Biovance 3L Ocular and Biovance are the only decellularized basement membranes designed to elevate the management of ocular surface disease and enhance ocular surgery outcomes.
Biovance 3L Ocular features a tri-layer architecture with a preserved epithelial basement membrane and intact extracellular matrix structure. This design promotes natural adherence to the ocular surface and facilitates cellular migration, supporting the body’s intrinsic healing response. Both products are available in six ring-free, bidirectional shapes and sizes, optimizing comfort and flexibility for a range of clinical applications.
All Biovance products are aseptically processed, terminally sterilized, and shelf-stable at room temperature, ensuring consistent performance and convenience for in-office and surgical settings.
“Ocular surface disease is a common condition that causes significant discomfort and visual impairment among those who have served our country,” said Rob Sambursky, MD, CEO of DefEYE, Inc. “We are proud to partner with Lovell to expand treatment options for military service members and veterans with our Biovance ocular portfolio of decellularized basement membranes. Biovance offers physicians an innovative option for both in-office and surgical use. By combining a biologic scaffold for cellular migration with active signaling proteins, our membranes deliver a more effective, clinically meaningful solution for managing ocular surface disease.”